SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations
The novel SARS-CoV-2 Variant of Concern (VOC)-202012/01 (also known as B.1.1.7), first collected in United Kingdom on 20 September 2020, is a rapidly growing lineage that in January 2021 constituted 86% of all SARS-CoV-2 genomes sequenced in England. The VOC has been detected in 40 out of 46 countri...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/3/392 |
_version_ | 1797416372650639360 |
---|---|
author | Frederic Grabowski Grzegorz Preibisch Stanisław Giziński Marek Kochańczyk Tomasz Lipniacki |
author_facet | Frederic Grabowski Grzegorz Preibisch Stanisław Giziński Marek Kochańczyk Tomasz Lipniacki |
author_sort | Frederic Grabowski |
collection | DOAJ |
description | The novel SARS-CoV-2 Variant of Concern (VOC)-202012/01 (also known as B.1.1.7), first collected in United Kingdom on 20 September 2020, is a rapidly growing lineage that in January 2021 constituted 86% of all SARS-CoV-2 genomes sequenced in England. The VOC has been detected in 40 out of 46 countries that reported at least 50 genomes in January 2021. We have estimated that the replicative advantage of the VOC is in the range 1.83–2.18 [95% CI: 1.71–2.40] with respect to the 20A.EU1 variant that dominated in England in November 2020, and in range 1.65–1.72 [95% CI: 1.46–2.04] in Wales, Scotland, Denmark, and USA. As the VOC strain will likely spread globally towards fixation, it is important to monitor its molecular evolution. We have estimated growth rates of expanding mutations acquired by the VOC lineage to find that the L18F substitution in spike has initiated a fast growing VOC substrain. The L18F substitution is of significance because it has been found to compromise binding of neutralizing antibodies. Of concern are immune escape mutations acquired by the VOC: E484K, F490S, S494P (in the receptor binding motif of spike) and Q677H, Q675H (in the proximity of the polybasic cleavage site at the S1/S2 boundary). These mutants may hinder efficiency of existing vaccines and expand in response to the increasing after-infection or vaccine-induced seroprevalence. |
first_indexed | 2024-03-09T06:03:18Z |
format | Article |
id | doaj.art-5e595ee0dcbf4257901813777eec5514 |
institution | Directory Open Access Journal |
issn | 1999-4915 |
language | English |
last_indexed | 2024-03-09T06:03:18Z |
publishDate | 2021-03-01 |
publisher | MDPI AG |
record_format | Article |
series | Viruses |
spelling | doaj.art-5e595ee0dcbf4257901813777eec55142023-12-03T12:07:09ZengMDPI AGViruses1999-49152021-03-0113339210.3390/v13030392SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning MutationsFrederic Grabowski0Grzegorz Preibisch1Stanisław Giziński2Marek Kochańczyk3Tomasz Lipniacki4Institute of Fundamental Technological Research, Polish Academy of Sciences, 02-106 Warsaw, PolandInter-Faculty Individual Studies in Mathematics and Natural Sciences, The MISMaP College, University of Warsaw, 02-097 Warsaw, PolandFaculty of Mathematics, Informatics and Mechanics, University of Warsaw, 02-097 Warsaw, PolandInstitute of Fundamental Technological Research, Polish Academy of Sciences, 02-106 Warsaw, PolandInstitute of Fundamental Technological Research, Polish Academy of Sciences, 02-106 Warsaw, PolandThe novel SARS-CoV-2 Variant of Concern (VOC)-202012/01 (also known as B.1.1.7), first collected in United Kingdom on 20 September 2020, is a rapidly growing lineage that in January 2021 constituted 86% of all SARS-CoV-2 genomes sequenced in England. The VOC has been detected in 40 out of 46 countries that reported at least 50 genomes in January 2021. We have estimated that the replicative advantage of the VOC is in the range 1.83–2.18 [95% CI: 1.71–2.40] with respect to the 20A.EU1 variant that dominated in England in November 2020, and in range 1.65–1.72 [95% CI: 1.46–2.04] in Wales, Scotland, Denmark, and USA. As the VOC strain will likely spread globally towards fixation, it is important to monitor its molecular evolution. We have estimated growth rates of expanding mutations acquired by the VOC lineage to find that the L18F substitution in spike has initiated a fast growing VOC substrain. The L18F substitution is of significance because it has been found to compromise binding of neutralizing antibodies. Of concern are immune escape mutations acquired by the VOC: E484K, F490S, S494P (in the receptor binding motif of spike) and Q677H, Q675H (in the proximity of the polybasic cleavage site at the S1/S2 boundary). These mutants may hinder efficiency of existing vaccines and expand in response to the increasing after-infection or vaccine-induced seroprevalence.https://www.mdpi.com/1999-4915/13/3/392COVID-19 pandemicSARS-CoV-2spike proteinVOC-202012/01spike L18Fgenome sequencing |
spellingShingle | Frederic Grabowski Grzegorz Preibisch Stanisław Giziński Marek Kochańczyk Tomasz Lipniacki SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations Viruses COVID-19 pandemic SARS-CoV-2 spike protein VOC-202012/01 spike L18F genome sequencing |
title | SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations |
title_full | SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations |
title_fullStr | SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations |
title_full_unstemmed | SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations |
title_short | SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations |
title_sort | sars cov 2 variant of concern 202012 01 has about twofold replicative advantage and acquires concerning mutations |
topic | COVID-19 pandemic SARS-CoV-2 spike protein VOC-202012/01 spike L18F genome sequencing |
url | https://www.mdpi.com/1999-4915/13/3/392 |
work_keys_str_mv | AT fredericgrabowski sarscov2variantofconcern20201201hasabouttwofoldreplicativeadvantageandacquiresconcerningmutations AT grzegorzpreibisch sarscov2variantofconcern20201201hasabouttwofoldreplicativeadvantageandacquiresconcerningmutations AT stanisławgizinski sarscov2variantofconcern20201201hasabouttwofoldreplicativeadvantageandacquiresconcerningmutations AT marekkochanczyk sarscov2variantofconcern20201201hasabouttwofoldreplicativeadvantageandacquiresconcerningmutations AT tomaszlipniacki sarscov2variantofconcern20201201hasabouttwofoldreplicativeadvantageandacquiresconcerningmutations |